٩(⁎❛ᴗ❛⁎)۶ try 1ClickImgur.com download imgur images and videos

Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer

Say and pronounce Dr. Garcia On on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the May 2017 FDA approval of pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   Durvalumab FDA Approval for Bladder Cancer   The FDA Approval of Atezolizumab in Bladder Cancer   Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma   21st Century Cures Act Passes and 2016 Highlights from SABCS and WCLC   Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC   FDA Approval of Durvalumab for Bladder Cancer   Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC   FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More   Upfront Use of Immunotherapy for NCSLC   Pembrolizumab in Newly Diagnosed Squamous NSCLC   Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC   Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and Breakthrough Designation in NSCLC   FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and a Breakthrough Designation in NSCLC   FDA Approval in AML, NDA Submitted in Myeloma, Clinical Hold on CAR T-cell Therapy Trials, and More   Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer   Upfront Immunotherapy for PD-L1+ NSCLC   Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer   Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer   FDA Approval of Durvalumab for Advanced Bladder Cancer   Combined Immunotherapy and Chemotherapy for NSCLC   Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More   Upfront Immunotherapy + Chemotherapy for NSCLC   FDA Approvals in NSCLC, Bladder Cancer, and Breast Cancer, and Death in CAR T-cell Therapy Trial   Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer   FDA Approval of Atezolizumab for Advanced Bladder Cancer   Upfront Immunotherapy for NSCLC   Dr. Garcia on Selecting Second-line Immunotherapy in Bladder Cancer   Immunotherapy for HNSCC   Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More   Dr. Garcia on Sequencing Immunotherapies in Bladder Cancer   Breakthrough In Leukemia Treatment   FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More   FDA Approval in Lung Cancer, Priority Reviews in HCC and NHL, and an ODAC Recommendation   Novartis Metastatic Breast Cancer Treatment   Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer   FDA Approvals in CRC, Blood Cancer Detection Diagnostic, and Alopecia, and More   FDA Approvals in Breast Cancer and Melanoma, Disappointing Results in HNSCC, and More   FDA Approvals in CRC, Blood Diagnostic, and Alopecia, and More   FDA Approval: Frontline Ceritinib for ALK+ NSCLC   FDA Approval in MZL, Delay in Immunotherapy Combos in NSCLC, and 2017 GI Symposium Highlights   FDA Approval in CLL, Recommendation in NSCLC, Missed Endpoint in GBM Study, and More   Activity of Immunotherapy in the Frontline Setting   FDA Approval in Breast Cancer, Breakthrough Designations in AML and Bladder Cancer, and More   Dr. Gandhi on Pembrolizumab/Chemo Findings in NSCLC and FDA Approval   Nivolumab Lung Cancer Approval Expanded, Abemaciclib Granted Breakthrough Status, and More   FDA Approval in Myeloma, Priority Review in ALL, and 2017 GU Cancers Symposium Highlights   Bladder Cancer Recurrence Discovered Through New Urine Test   Dr. Blackwell on Neratinib in HER2+ Breast Cancer   'Our Cancer Drug Is For Rich Westerners, Not Poor Indians'   Frontline Atezolizumab for Advanced Bladder Cancer   FDA Approval of Brigatinib for ALK+ NSCLC   FDA Approvals in Hematologic Malignancies, sBLA Accepted in Multiple Myeloma, and More   2015 AACR Annual Meeting Highlights   FDA approves breakthrough CAR-T therapy for leukemia   Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder Cancer   FDA Approval in Lung Cancer, Promising Findings in Hodgkin Lymphoma, and More   Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC   Bradley C. Leibovich, M.D.: Urologist - Mayo Clinic   Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL   FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More   Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC   Dr. Al-Kali on FDA Approval of Enasidenib in AML   Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer   FDA Approval in AML, Priority Review Designation in NSCLC, and More   Niraparib Maintenance for Recurrent Ovarian Cancer   Dr. Black on Sequencing of Immunotherapy in Bladder Cancer   Dr. Reidy-Lagunes on FDA Approval of Telotristat Epitrate for Carcinoid Syndrome   FDA Approvals in ALL and Breast Cancer, Priority Reviews in CML and Follicular Lymphoma, and More   Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer   FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and More

Popular Today